BMS-488043

CAS No. 452296-83-2

BMS-488043( —— )

Catalog No. M34526 CAS No. 452296-83-2

BMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 210 Get Quote
5MG 323 Get Quote
10MG 485 Get Quote
25MG 762 Get Quote
50MG 1058 Get Quote
100MG 1395 Get Quote
500MG 2673 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BMS-488043
  • Note
    Research use only, not for human use.
  • Brief Description
    BMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.
  • Description
    BMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.BMS-488043 is used for the treatment of immune disorders, infections, and genitourinary disorders, and can be used in the study of HIV infect
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    452296-83-2
  • Formula Weight
    422.43
  • Molecular Formula
    C22H22N4O5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(=O)N1CCN(C(=O)C2=CC=CC=C2)CC1)(=O)C=3C=4C(=C(OC)N=CC4OC)NC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • (±)-BI-D

    A potent, allosteric HIV integrase inhibitor (Kd=34 nM) that binds the LEDGF/p75 binding site on integrase.

  • I-XW-053

    I-XW-053 is an inhibitor of capsid targeted HIV-1 replication using the hybrid structure based method to block the interface between CA N-terminal domains (NTD-NTD interface) with micromolar affinity.

  • Darunavir ethanolate

    A potent, selective HIV-1 protease inhibitor that is extremely potent against laboratory HIV-1 strains and primary clinical isolates with IC50 of 3 nM, IC90 of 9 nM.